Skip to main content

Sangamo/Pfizer's Giroctocogene Fitelparvovec Gene Therapy for Hemophilia- Clinical Update

Introduction of Giroctocogene Fitelparvovec Gene Therapy for Hemophilia A

Giroctocogene Fitelparvovec is an investigational gene therapy product for the treatment of Hemophilia A co-developed by Sangamo/Pfizer. Giroctocogene fitelparvovec (SB-525) is a liver-tropic recombinant adeno-associated virus (rAAV6) vector carrying a B-domain–deleted F8 gene that is delivered through a single IV infusion.

Sponsor: Sangamo Therapeutics/ Pfizer
Stage-  Phase 3
Phase 2 - NCT03061201
Phase 3 - NCT04370054 (First Patient Dose) 

Clinical Outcome 
Efficacy: Efficacy was observed with significant reduction of annualized bleeding rate and usage of factor VIII infusion in phase 2 at the vector dose 3e13 vg/kg (viral genome/kg) upto 36 weeks after treatment.

Safety: In phase 2 clinical studies, 4/5 subject at a vector dose of 3e13 vg/kg showed transient elevation of transaminases and required corticosteroid therapy. One treatment related SAE was observed. 

Durability: The gradual decline of the factor VIII activity after peaking at 23-26 weeks was observed in four year follow up of AAV5-FVIII hemophilia treatment developed by Biomarin.  In this phase 2 clinical study, factor VIII peaked at week 9 and the stable expression was observed up to 36 weeks follow up. Longer term study will should provide more information on the durability of the expression. 
...........................................

Sangamo Phase 3 Study (AFFINE) Update

AFFINE is a global Phase 3, open-label, multicenter, single arm study that will evaluate the efficacy and safety of giroctocogene fitelparvovec in patients with moderately severe to severe hemophilia A. 

The primary endpoint is impact on annual bleed rate (ABR) through 12 months following treatment with giroctocogene fitelparvovec, compared to ABR on Factor VIII (FVIII) replacement therapy collected in the Phase 3 lead-in study period. 

Participants will be analyzed throughout the 5-year study period following the single infusion to further assess the durability and efficacy.

On October 7, 2020; the first participant were dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients.
........................................

 Key Finding From Phase 2 (Alta) Study Updated on June 18, 2020

Efficacy from Cohort 4 (3x1013 vg/kg)
  • Steady-state FVIII activity achieved by week 9 post infusion
  • FVIII activity values available up to week 30 and up to week 61
  • Median steady-state (of geometric means since week 9) FVIII activity level 64.2% via central laboratory chromogenic assay
  • No bleeding events 
  • No FVIII infusions beyond initial use of prophylactic factor
Summary of Results from Phase 2 Clinical Study (WHF2020)


.....................................................
Reference
Sangamo Therapeutics
Pfizer
ClinicalTrail.gov
Labels:

Comments

Post a Comment

Popular posts from this blog

Carbohydrate Metabolism: MCQs and answers on Glycolysis & Gluconeogenesis

                                      MCQ on Glycolysis & Gluconeogenesis 1) Which of the following enzyme is not involved in galactose metabolism? a) Glucokinase b) Galactokinase c) Galactose-1-Phosphate Uridyl transferase d) UDP-Galactose 4- epimerase 2) Which of the following enzyme is defective in galactosemia (type I) - a fatal genetic disorder in infants? a) Glucokinase b) Galactokinase c) Galactose-1-Phosphate Uridyl transferase d) UDP-Galactose 4- epimerase 3) In the liver, the accumulation of which of the following metabolite attenuates the inhibitory of ATP on phosphofructokinase? a) Glucose-6-Phosphate b) Citrate c) Fructose-1,6-Bisphosphate d) Fructose-2,6-Bisphosphate 4) Mutation in which of the following enzymes leads to a glycogen storage disease known as "Tarui’s disease"? a) Glucokinase b) Phosphofructokinase c) Phosphoglucomutase d) Pyruvate Kinase 5) E...
Read More

MCQs and Answers on cultivation (culture/incubation), Isolation and Identification of microorganisms: Medical Microbiology

40 plus questions - Multiple Choice Questions on Classification, Culture, and Identification of the microorganisms 1. Which of the following microorganism has the cocci cell shapes and sizes arranged usually in tetrad structures? a)  Streptococcus pneumoniae b)  Staphylococcus aureus c)  Chlamydia trachomatis d)  Neisseria meningitidis 2. What are the different growth morphology and cell structures used for the classification of fungi? Select all the correct answers: a) Yeast b) Mold c) Mycelia d) Protozoa 3. Which of the following media is formulated with additional nutrients to support the growth of fastidious or nutritionally demanding bacteria that may not grow well on basic media? a) Differential media b) Enriched media c) Nutrient agar (media) d) Selective media 4. Which of the following metabolic characteristic is a distinguishing characteristic and identification of colonies of  E. coli ? a) Hydrogen sulfide formation b) Indole Formation c) Lactose fe...
3 comments
Read More

Multiple Choice Questions (MCQs) on Diabetes Mellitus: Pathogenesis, Diagnosis and Treatment

                                        MCQs on Diabetes mellitus 1) Diabetes mellitus is a disorder characterized by hyperglycemia.  Which of the following is not the common characteristic features of type 2 diabetes mellitus ? a) Impaired insulin secretion b) Increased Insulin resistance  c) Diabetic ketoacidosis d) Excessive hepatic glucose production 2) Which of the following are the characteristic features of type 1 diabetes mellitus? a) Type 1 diabetes is caused by an absolute deficiency of insulin. b) Type 1 diabetes is associated with the autoimmune destruction of beta cells.  c) Patients with  uncontrolled type 1 diabetes present with diabetic ketoacidosis d) All of the above   3) Which of the following serum measurements are not used for the diagnosis of diabetes mellitus? a) Fasting blood glucose d) Postprandial blood glucose  c) Insulin ...
5 comments
Read More